The inevitable conquest of Zoldex is set in motion. The war for the fate of the Imperium has begun!The conclusion of the Fall of the Imperium Trilogy is gripping and exciting. The legions of Zoldex have swept the land, and their conquest is almost complete! The heroes of the realm struggle desperately to seek new alliances to combat the overwhelming forces of their foe. No matter how hard they try, the odds are against them, and the heroes find themselves being pushed back. The Imperium will truly fall, and life will never be the same again.

Fleeing from their homes, the survivors of the once mighty Madrew are refugees searching to rebuild their civilization. The Elders have prophesized one individual, a child that will defeat the threat of the tyrant Zoldex and return the Madrew to their former glory. This child is Kyria, the Chosen One.

The Mage's Academy is like no other school in the Seven Kingdoms. Just when Kyria thought that she knew what to expect, she learns of the Shard of Time, a mystical artifact that has the power to send people back in time and experience events as they actually unfolded.

After learning that she inherited a BRCA2 genetic mutation that put her at high risk for breast and ovarian cancer, Kim Horner’s doctors urged her to consider having a double mastectomy. But how do you decide whether to have a surgery to remove your breasts to reduce your risk for a disease you don’t have and may never get? Horner shares her struggle to answer that question in Probably Someday Cancer. The mother of a one-year-old boy, she wanted to do whatever would give her the best odds of being around for her son and protect her from breast cancer, which killed her grandmother and great-grandmother in their 40s. Which would give her the best chance at a long healthy life: a double mastectomy or frequent screenings to try to catch any cancer early? The answers weren’t that simple. Based on extensive research, interviews, and personal experience, Horner writes about how and why she ultimately opted for a double mastectomy—the same decision actress Angelina Jolie made for a similar genetic mutation—and the surprising diagnosis that followed. The book explores difficult truths that get overshadowed by upbeat messages about early detection and survivorship—the fact that screenings can miss cancers and that even early-stage breast cancers can spread and become fatal. Probably Someday Cancer is about the author’s efforts to push past her fear and anxiety. This book can help anyone facing hereditary risk of breast and ovarian cancer feel less alone and make informed decisions to protect their health and end the devastation that hereditary cancer has caused for generations in so many families.

The year is 2217, and Commander Frank Yamane is the captain of the stellar cruiser, Corona, stationed at Saturn's moon, Titan. Having been in the military for most of his life, he is a battle-hardened man who has experienced a series of personal tragedies, including the loss of his beloved wife, Liana. The inability to prevent her death has left him feeling guilt-ridden, and plagued with doubts regarding his ability to lead others. It is these same experiences, however, that have also prepared him for when humanity needs him most when an alien race known as the Deravans attack the Earth without mercy. Knowing he cannot stop them alone, Yamane has no choice but to seek the assistance of an enemy he helped defeat in a war ten years before. The problem is, Commander Yamane knows they have every reason not to come to Earth's rescue.

Corporations have found a new resource to be mined for profit: our children. In this shocking and indelible behind-the-scenes journey, Joel Bakan, acclaimed author and award-winning maker of the renowned film and international bestselling book The Corporation, uncovers the astonishing degree to which companies exploit the special vulnerabilities of children, manipulate parents’ fears, and operate with callous disregard for children’s health and well-being. The number of children taking dangerous psychotropic drugs has skyrocketed as pharmaceutical companies employ insidious, often illegal tactics to inflate diagnoses of disorders and convince parents their children require medication. A highly sophisticated marketing industry deploys increasingly subtle and powerful tactics to play on children’s intense emotions and desires and to lure them into obsessive consumerism. Computer game designers craft techniques to titillate children with sex and violence, while social media developers infiltrate and shape children’s social and emotional worlds to compel them to spend more and more monetizable time online. America’s schools are being transformed into profit centers while children are subjected to increasingly regimented teaching that thwarts curiosity and creativity, numbing the joy of learning. And children’s chronic health problems, from asthma to cancer, autism, and birth defects, steadily escalate as thousands of new industrial chemicals are dumped into their environments. Nelson Mandela once sagely remarked that “there can be no keener revelation of a society’s soul than the way it treats its children.” The problem today, as Joel Bakan reveals, is that business interests have made protecting children extremely difficult. Corporations pump billions into rendering parents and governments powerless to shield children from an unrelenting commercial assault, with the result that after a century of progress, during which protective laws and regulations were widely promulgated, children are once again exposed to substantial harms at the hands of economic actors. Childhood Under Siege leaves no room for doubt that this assault on childhood is a major crisis of our time. A powerful manifesto for urgent change, it empowers us to shield our own children while offering concrete and realistic proposals for legal reforms that would protect all children from these predatory practices.

The range of controversial therapies and treatments for prostate cancer is greater than that of any other cancer affecting men. Many of the current books on prostate cancer suffer from considerable bias promoting one treatment over another without good scientific evidence. "Winning the Battle Against Prostate Cancer" is an unbiased and up-to-date look at prostate cancer treatments and therapies, resolving the problem of contradictory and incomplete information. Dr. Chodak outlines the pros and cons of all reasonable treatment options, recognizing that men and their families need more than just the facts -- they are concerned not only with their survival but also what life will be like after treatment. This book offers empathetic insight into the impact of the disease on day-to-day activities so that patients and family members have a clear understanding of what lies ahead and options that are available should complications arise. The book does not gloss over the controversies but presents them in a clear, concise, and easy-to-understand manner.

To facilitate the development of novel drug delivery systems and biotechnology-oriented drugs, the need for new, yet to be developed, and approved excipients continues to increase. Excipient Development for Pharmaceutical, Biotechnology, and Drug Delivery Systems serves as a comprehensive source to improve understanding of excipients and forge potential new avenues for regulatory approval. This book presents detailed, up-to-date information on various aspects of excipient development, testing, and technological considerations for their use. It addresses specific details such as historical perspective, preclinical testing, safety, and toxicology evaluation, as well as regulatory, quality, and utility aspects. The text also describes best practices for use of various functional excipients and extensive literature references for all topics.

This book elaborates on drug delivery targeting via intracellular delivery, specifically through the Receptor Mediated Endocytosis (RME) approach, due to the involvement of cellular receptors in various grave diseases. Targeted delivery relies on two basic approaches, passive and active targeting. While passive targeting approaches have shown great promise, the improved selectivity achieved with active targeting approaches has resulted in significantly higher efficacy. Interestingly there are numerous strategies for active targeting, many of which are already highlighted in , Targeted Drug Delivery: Concepts and Applications. Nevertheless an exciting and practical strategy for active targeting, which could enable high intracellular delivery, is through exploitation of RME. Cells in the body express receptors to enable various physiological and biochemical processes. As a result, many of these receptors are overexpressed in pathological conditions, or newer receptors expressed due to defective cellular functioning. RME is based on exploitation of such receptors to achieve intracellular delivery. While targeted delivery can have manifold applications, in this book we focus on two major and challenging therapeutic areas; i) Cancer and ii) Infectious Diseases. Targeted Intracellular Drug Delivery by Receptor Medicated Endocytosis discusses the major receptors that are useful for targeted delivery for these afflictions. A major section of this book is dedicated to details regarding their occurrence and location, the recognition domain of the receptor, structure activity relationship of substrate /ligand for selective binding, ligands explored, antagonists for ligand binding and relevance of these aspects for therapy of cancer and infectious diseases. These facets are elucidated with the help of specific examples from academic research and also emphasize commercial products, wherever relevant. In vitro cellular models relied on for assessing receptor mediated cellular targeting and in vivo models depicting clinical efficacy are focused on in a separate section. Finally, we briefly discuss the regulatory and toxicity issues that may be associated specifically with the RME approach of intracellular drug delivery.